{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:10:09Z","timestamp":1793214609664,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autoimmune inflammatory ocular diseases, including uveitis, scleritis, and ocular mucous membrane pemphigoid, can cause severe, vision-threatening complications and are often associated with systemic autoimmune conditions. Standard therapies involve corticosteroids, conventional disease-modifying antirheumatic drugs (cDMARDs), and biologics, yet some cases remain refractory. Janus kinase (JAK) inhibitors have emerged as a promising therapeutic option for such refractory cases and are increasingly being explored as potential primary or secondary line therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>This systematic review synthesized evidence from case reports and case series describing the use of JAK inhibitors in non-infectious ocular inflammation. A comprehensive search of PubMed and MEDLINE (from inception to March 2025) identified 22 studies (12 case reports, 10 case series) involving 43 patients (64 eyes). Patients ranged from 13 to 85 years (mean\u2009=\u200941) with a female predominance (69.7%). Reported ocular conditions included scleritis (46.5%), uveitis (34.9%), ocular mucous membrane pemphigoid (7.0%), keratitis (4.7%), keratoconjunctivitis (4.7%), and non-specific orbital inflammation (2.3%). Most patients had failed prior therapies with corticosteroids, cDMARDs (80%), and biologics (51%) before initiating JAK inhibitors. Tofacitinib (62.8%) was the most frequently used agent.<\/jats:p>\n                    <jats:p>The median follow-up was approximately 2.5 months (range: 1\u201378 months). Complete remission was achieved in 69.7% of patients, while 27.9% experienced partial or marked improvement. More than half of the patients were able to taper or discontinue corticosteroids. No relapses were reported during follow-up. Reported adverse events were mild and included elevated transaminases, leukopenia, neutropenia, and herpes virus reactivation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>JAK inhibitors demonstrate promising efficacy and an acceptable safety profile in refractory autoimmune ocular inflammatory diseases, enabling high rates of remission and reduced steroid dependence. These findings highlight their potential role in treatment algorithms and underscore the need for further prospective studies to define their long-term efficacy, safety, and optimal use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12348-025-00537-y","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T03:36:03Z","timestamp":1765337763000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["JAK inhibitors in autoimmune ocular inflammatory diseases \u2013 A systematic review of case reports and series"],"prefix":"10.1186","volume":"15","author":[{"given":"Salem","family":"Almerri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamad","family":"Alshatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef Taleb","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed","family":"Behbehani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"issue":"3","key":"537_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12016-015-8518-3","volume":"49","author":"E Generali","year":"2015","unstructured":"Generali E, Cantarini L, Selmi C (2015) Ocular involvement in systemic autoimmune diseases. Clin Rev Allergy Immunol 49(3):263\u2013270","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"537_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12348-017-0124-5","volume":"7","author":"MA Bin Ismail","year":"2017","unstructured":"Bin Ismail MA et al (2017) Ocular autoimmune systemic inflammatory infectious study (OASIS)-report 4: analysis and outcome of scleritis in an East Asian population. J Ophthalmic Inflamm Infect 7(1):6","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"1\u20132","key":"537_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40123-014-0023-x","volume":"3","author":"C Castiblanco","year":"2014","unstructured":"Castiblanco C, Foster CS (2014) Review of systemic immunosuppression for autoimmune uveitis. Ophthalmol Ther 3(1\u20132):17\u201336","journal-title":"Ophthalmol Ther"},{"key":"537_CR4","doi-asserted-by":"publisher","first-page":"p2324400","DOI":"10.1155\/2021\/2324400","volume":"2021","author":"J Wen","year":"2021","unstructured":"Wen J et al (2021) Role of Janus kinase (JAK) inhibitor in autoimmune ocular inflammation: A systematic review. J Immunol Res 2021:p2324400","journal-title":"J Immunol Res"},{"issue":"0 2","key":"537_CR5","doi-asserted-by":"publisher","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","volume":"72","author":"JJ O\u2019Shea","year":"2013","unstructured":"O\u2019Shea JJ et al (2013) Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 72(0 2):ii111\u2013ii115","journal-title":"Ann Rheum Dis"},{"key":"537_CR6","doi-asserted-by":"publisher","first-page":"115236","DOI":"10.1016\/j.bcp.2022.115236","volume":"204","author":"Y Su","year":"2022","unstructured":"Su Y et al (2022) JAK-STAT signaling pathway in non-infectious uveitis. Biochem Pharmacol 204:115236","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"537_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH et al (2018) Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med 23(2):60\u201363","journal-title":"BMJ Evid Based Med"},{"issue":"1","key":"537_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/flgastro-2023-102400","volume":"15","author":"S Honap","year":"2024","unstructured":"Honap S et al (2024) JAK inhibitors for inflammatory bowel disease: recent advances. Frontline Gastroenterol 15(1):59\u201369","journal-title":"Frontline Gastroenterol"},{"key":"537_CR9","doi-asserted-by":"crossref","unstructured":"Harrington R, Harkins P, Conway R (2023) Janus kinase inhibitors in rheumatoid arthritis: an update on the efficacy and safety of Tofacitinib, baricitinib and Upadacitinib. J Clin Med, 12(20)","DOI":"10.3390\/jcm12206690"},{"issue":"10","key":"537_CR10","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/art.41384","volume":"72","author":"R van Vollenhoven","year":"2020","unstructured":"van Vollenhoven R et al (2020) Efficacy and safety of Upadacitinib monotherapy in Methotrexate-Naive patients with Moderately-to-Severely active rheumatoid arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, active Comparator-Controlled trial. Arthritis Rheumatol 72(10):1607\u20131620","journal-title":"Arthritis Rheumatol"},{"issue":"25","key":"537_CR11","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB et al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370(25):2377\u20132386","journal-title":"N Engl J Med"},{"issue":"7","key":"537_CR12","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC et al (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376(7):652\u2013662","journal-title":"N Engl J Med"},{"issue":"9","key":"537_CR13","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamaophthalmol.2024.2439","volume":"142","author":"SK Srivastava","year":"2024","unstructured":"Srivastava SK et al (2024) Filgotinib in active noninfectious uveitis: the HUMBOLDT randomized clinical trial. JAMA Ophthalmol 142(9):789\u2013797","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"537_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1186\/s13063-021-05651-5","volume":"22","author":"AV Ramanan","year":"2021","unstructured":"Ramanan AV et al (2021) Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT). Trials 22(1):689","journal-title":"Trials"},{"issue":"12","key":"537_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1167\/iovs.64.12.28","volume":"64","author":"Z Huang","year":"2023","unstructured":"Huang Z et al (2023) Therapeutic effects of Upadacitinib on experimental autoimmune uveitis: insights from Single-Cell analysis. Invest Ophthalmol Vis Sci 64(12):28","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"537_CR16","doi-asserted-by":"publisher","first-page":"110660","DOI":"10.1016\/j.intimp.2023.110660","volume":"122","author":"T Li","year":"2023","unstructured":"Li T et al (2023) Current application status and structure-activity relationship of selective and non-selective JAK inhibitors in diseases. Int Immunopharmacol 122:110660","journal-title":"Int Immunopharmacol"},{"key":"537_CR17","doi-asserted-by":"publisher","first-page":"977265","DOI":"10.3389\/fimmu.2022.977265","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L et al (2022) Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis. Front Immunol 13:977265","journal-title":"Front Immunol"},{"issue":"1","key":"537_CR18","doi-asserted-by":"publisher","first-page":"105483","DOI":"10.1016\/j.jbspin.2022.105483","volume":"90","author":"S Hecquet","year":"2023","unstructured":"Hecquet S et al (2023) Ophthalmic adverse events under Tofacitinib and baricitinib: case analysis of the European pharmacovigilance database. Joint Bone Spine 90(1):105483","journal-title":"Joint Bone Spine"},{"issue":"3","key":"537_CR19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0733-8635(18)30318-8","volume":"10","author":"L Renfro","year":"1992","unstructured":"Renfro L, Snow JS (1992) Ocular effects of topical and systemic steroids. Dermatol Clin 10(3):505\u2013512","journal-title":"Dermatol Clin"},{"issue":"1","key":"537_CR20","doi-asserted-by":"publisher","first-page":"15537","DOI":"10.1038\/s41598-023-42371-z","volume":"13","author":"FR Spinelli","year":"2023","unstructured":"Spinelli FR et al (2023) Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with Tofacitinib. Sci Rep 13(1):15537","journal-title":"Sci Rep"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-025-00537-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-025-00537-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-025-00537-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T16:49:33Z","timestamp":1765558173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12348-025-00537-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["537"],"URL":"https:\/\/doi.org\/10.1186\/s12348-025-00537-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7215848\/v1","asserted-by":"object"}]},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}